Cefpodoxime Proxetil (cefpodoxime proxetil)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Cefpodoxime is a semisynthetic, third generation cephalosporin antibiotic.
Cefpodoxime proxetil is used orally for the treatment of mild to moderate respiratory tract infections (i.e., acute exacerbations of chronic bronchitis, acute maxillary sinusitis, community-acquired pneumonia) caused by susceptible bacteria; the treatment of acute otitis media caused by susceptible bacteria; and the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A beta-hemolytic streptococci). The drug also is used orally for the treatment of uncomplicated gonorrhea and for the treatment of mild to moderate uncomplicated skin and skin structure or uncomplicated urinary tract infections caused by susceptible bacteria.
Generic name: cefpodoxime proxetil
Pronunciation: (seff-poh-DOX-eem PROX-eh-til)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Cefpodoxime Proxetil
Indications
The following indications are listed for Cefpodoxime Proxetil:
- Acute Bacterial Otitis Media
- Acute Maxillary Haemophilus Influenzae Sinusitis
- Acute Maxillary Moraxella Catarrhalis Sinusitis
- Acute Maxillary Streptococcus Pneumoniae Sinusitis
- E. Coli Urinary Tract Infection
- Haemophilus Influenzae Bronchitis
- Haemophilus Influenzae Pneumonia
- Klebsiella Urinary Tract Infection
- Moraxella Catarrhalis Bronchitis
- Pharyngitis Due To Streptococcus Pyogenes
- Pneumococcal Pneumonia
- Proteus Urinary Tract Infection
- Skin And Skin Structure Streptococcus Pyogenes Infection
- Staphylococcus Aureus Skin And Skin Structure Infection
- Staphylococcus Saprophyticus Urinary Tract Infection
- Streptococcus Pneumoniae Bronchitis
- Tonsillitis Due To Streptococcus Pyogenes
Also known as: Acute Maxillary Sinusitis Due To B. Catarrhalis, Acute Maxillary Sinusitis Due To Branhamella Catarrhalis, Acute Maxillary Sinusitis Due To Diplococcus Pneumoniae, Acute Maxillary Sinusitis Due To Fraenkel's Pneumococcus, Acute Maxillary Sinusitis Due To H. Flu, Acute Maxillary Sinusitis Due To Haemophilus Influenzae, Acute Maxillary Sinusitis Due To Hemophilus Influenzae, Acute Maxillary Sinusitis Due To Influenza Bacillus, Acute Maxillary Sinusitis Due To Moraxella Catarrhalis, Acute Maxillary Sinusitis Due To Neisseria Catarrhalis, Acute Maxillary Sinusitis Due To Pfeiffer's Bacillus, Acute Maxillary Sinusitis Due To Pneumococcus, Acute Maxillary Sinusitis Due To Pneumonococcus, Acute Maxillary Sinusitis From Streptococcus Pneumoniae, Bacterial Otitis Media, Bronchitis Due To B. Catarrhalis, Bronchitis Due To Branhamella Catarrhalis, Bronchitis Due To Diplococcus Pneumoniae, Bronchitis Due To Fraenkel's Pneumococcus, Bronchitis Due To Fraenkel-Weichselbaum Pneumococcus, Bronchitis Due To H. Flu, Bronchitis Due To H. Influenzae, Bronchitis Due To Haemophilus Influenzae, Bronchitis Due To Hemophilus Influenzae, Bronchitis Due To Influenzae Bacillus, Bronchitis Due To M. Catarrhalis, Bronchitis Due To Moraxella Catarrhalis, Bronchitis Due To Neisseria Catarrhalis, Bronchitis Due To Pfeiffer's Bacillus, Bronchitis Due To Pneumococcus, Bronchitis Due To Pneumonococcus, Bronchitis Due To Streptococcus Pneumoniae, E. Coli Uti, Epidemic Sore Throat, H. Flu Pneumonia, H. Influenzae Pneumonia, Hemophilus Influenzae Pneumonia, Influenza Bacillus Pneumonia, Klebsiella Uti, Pfeiffer's Bacillus Pneumonia, Pharyngitis Due To Group A Beta-Hemolytic Streptococci, Pharyngitis Due To Streptococcus Epidemicus, Pneumonia Due To Haemophilus Influenzae, Pneumonia Due To Streptococcus Pneumoniae, Septic Sore Throat, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Streptococcal Pharyngitis, Streptococcus Pyogenes Tonsillitis, Urinary Tract Infection Due To Escherichia Coli, Urinary Tract Infection Due To Klebsiella Species, Urinary Tract Infection Due To Proteus Species, Uti Due To Proteus Species, Uti Due To Staphylococcus Saprophyticus.
Dosing
Cefpodoxime is commercially available as cefpodoxime proxetil; dosage is expressed in terms of cefpodoxime.
Patients with creatinine clearances of 30 mL/minute or greater may receive the usual dosage of cefpodoxime.
Patients with creatinine clearances less than 30 mL/minute should receive the usual dose of cefpodoxime given once every 24 hours. Patients maintained on hemodialysis should receive the usual dose 3 times weekly following dialysis.
The manufacturer states that modification of the usual dosage of cefpodoxime is not necessary in patients with hepatic impairment.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats or rabbits using cefpodoxime dosages up to 100 mg/kg daily (approximately 2 times the usual human dosage on a mg/m2 basis) or 30 mg/kg daily (approximately 1-2 times the usual human dosage on a mg/m2 basis), respectively, have not revealed evidence of teratogenicity or harm to the fetus. There are no adequate and controlled studies using cefpodoxime proxetil in pregnant women or during labor and delivery, and the drug should be used during pregnancy only when clearly needed.
Cefpodoxime is distributed into milk in low concentrations following oral administration. Because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.